Donald Berry is professor in the Department of Biostatistics of the University of Texas M.D. Anderson Cancer Center. He received his Ph.D. in statistics from Yale University and has held endowed faculty positions at Duke University and M.D. Anderson. He has designed and supervised the conduct of many innovative clinical trials, including adaptive Bayesian trials, in cancer and other diseases. A principal focus of his research is the use of biomarkers for learning which patients benefit from which therapies, based on genomics and phenotype. In particular, he designed and is a co-PI of I-SPY 2 www.ispy2.org, a Bayesian adaptive platform clinical trial in high-risk early breast cancer. He has authored many books on biostatistics and over 400 peer-reviewed articles. He is a Thomson Reuters Highly Cited Researcher in recognition of ranking among the top 1% of most cited researchers in Clinical Medicine. He has received numerous research grants from the NIH and NSF and is Fellow of the American Statistical Association and of the Institute of Mathematical Statistics. He is founder and co-owner of Berry Consultants, a company that designs innovative clinical trials for industry, cooperative groups, international consortia, and patient advocacy groups.